Cardinal begins construction on Dublin headquarters
Cardinal Health is beginning construction on a $50 million expansion of its Dublin Headquarters.
The new west campus facility will be for the company’s Healthcare Supply Chain Services sector. This sector of the company, which will be a result of a new combination between its pharmaceutical and medical products business, that accounted for 97 percent of its fiscal 2007 revenue will nearly double the size of the company’s campus.
The company will add 700 jobs to its office through the expansion, and the new facility will hold offices for 500 employees from the Dublin office.
Cardinal Health recorded a $1.9 billion profit in fiscal 2007 and employs more than 43,000 people worldwide.
FDA increases potency of levothyroxine products
WASHINGTON The Food and Drug Administration is strengthening the potency specifications for levothyroxine sodium to ensure the drug retains its potency over its entire shelf life.
The agency is increasing the specifications from a 90 to 110 percent potency range to a 95 to 105 percent range. The percent ranges were changed following concerns about the product by healthcare professionals and patients.
Data taken by the FDA showed that some of the levothyroxine products like blister packs degrade quicker than other package types. Also, some of the strengths have been shown to degrade more rapidly than others.
Manufacturers and marketers have two years to comply with the revised specification. Levothyroxine sodium products are used by over 13 million patients.
FDA to review heart problems from osteoporosis drugs
WASHINGTON The Food and Drug Administration is looking at new safety data on reports of atrial fibrillation in patients taking bisphosphonates.
Bisphosphonates are used to treat osteoporosis. The FDA is looking into the issue after a study in the May 3rd issue of the New England Journal of Medicine reported increased rates of serious atrial fibrillation in patients taking Fosamax and Reclast.
The FDA has performed an initial review and found that there was not a large enough group of people who were at risk for atrial fibrillation and would not as of right now ask for healthcare professionals to change their prescribing habits or to tell patients to change their use of the drugs.
The agency is seeking additional data to perform an in-depth review of the issue that could take up to one year to conclude.